FDA approves Zynyz for advanced anal cancer, marking a breakthrough for the 10,000 diagnosed annually—including actress ...

Author Julia DeVillers was daignosed with anal cancer and as it progresses, she was told she had 48 hours to live. Her ...

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

A kinder treatment for anal cancer involving a lower dose and shorter course of radiotherapy is more effective than ...

Cases of anal cancer have been rising significantly across the world, with doctors being able to identify who is at the most ...

White women over 65 experienced the most significant increase, with rates climbing 4.3% annually to reach 11.4 cases per ...

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Short-term results from a recent trial suggest that reduced-dose chemoradiotherapy may achieve high local control with less ...

Anal cancer rates are increasing most rapidly among white and Hispanic women over 65, a group not traditionally seen as ...